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Figure 1. Inﬂuence of KIR Telomeric-A (Tel-A) motifs on [A] the development
of PTLD after allogeneic HCT; and [B] NK cell response against EBV trans-
formed cells.
Table
Characteristics of 2nd UCBT
Characteristics of 2ndUCBT
Gender N %
Male 30 83.3
Primary Disease
Heme malignancy 16 44.4
Inherited metabolic disease 10 27.8
Marrow failure 4 11.1
Immunodeﬁciency 3 8.3
Hemoglobinopathy 3 8.3
Reason for 2nd UCBT
Primary graft failure 25 69.4
Late graft failure 3 8.33
Autologous recovery 8 22.2
Demographics median range
Age at 2nd UCBT (years) 7.4 1.5-20.9
Weight at 2nd UCBT (kg) 22.9 9.0-108.0
Time from 1st to 2nd UCBT (days) 61.5 42-3454
Cell Dose (n[39)
Cryopreserved TNCs x 107/kg 5.6 1.3-21.9
Reinfused TNCs x 107/kg 4.6 1.1-18.1
Reinfused CD34+ x 105/kg 1.4 0.1-15.0
Reinfused CD3+ x 106/kg 9.1 1.5-34.4
Reinfused CFUs x 104/kg 5.7 0.0-175.4
Abstracts / Biol Blood Marrow Transplant 21 (2015) S30eS53 S37Conclusions: NK cell responsiveness, a function of KIR gene
repertoire has a profound effect on the development of PTLD.
KIR genotype based identiﬁcation of HCT donor-recipient
pairs at high risk of developing PTLD will enable closer
monitoring of EBV DNAemia and facilitate prompt therapy.Figure.16
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Background: In the past 20 years, use of UCBT has improved
access to transplantation, particularly in children and ethnic
minorities. Rapid donor availability, partial HLA matching
and low incidence of graft versus host disease (GVHD) are
important advantages. UCBT outcomes have signiﬁcantly
improved in the last decade due to better graft availability
and donor selection. However, a small fraction of recipients
develop auto-recovery or graft failure and are candidates for
a second transplant. In most cases, due to urgency and
original limitations in donor choices, another cord blood unit
(CBU) is the best option for these children.Methods: Retrospective analysis of all pediatric patients
(<21 years) undergoing UCBT at Duke between 1995 and
2013 who subsequently received a second UCBT due to
graft failure or auto-recovery after the ﬁrst UCBT (n¼36)
was conducted. Patients requiring second transplants for
relapse were excluded. Kaplan-Meier estimates of overall
survival (OS) and cumulative incidence (CI) of engraftment
and GVHD were calculated. All received reduced intensity
conditioning for the second transplant. The most common
prep regimen was cyclophosphamide 60mg/kg x 2 and
equine ATG 30mg/kg x 3 (n¼15). Single cord (n¼28),
double cord (n¼3) or cord +haplo graft (n¼5) were the
donor sources. Demographic, disease and graft character-
istics are shown in the Table.
Results: The OS at 100 days, 1 year and 5 years was 50.0%,
37.1% and 33.3% respectively. Mortality was lower for pa-
tients transplanted after 2007, but the difference was not
statistically signiﬁcant (p¼0.33) (see Figure). Median time to
neutrophil (ANC 500) and platelet (50K) engraftments were
27 (range, 12-94) and 98 days (range, 37-434) respectively.
The probability of neutrophil engraftment at day 42 was
64.3%. The CI of grades II-IV and grades III-IV acute GVHD, at
100 days was 47.1% and 31.3% respectively. Extensive/chronic
GVHD was seen in 3 patients (CI¼13.6%).
Abstracts / Biol Blood Marrow Transplant 21 (2015) S30eS53S38Conclusions: Second UCBT resulted in acceptable survival
particularly in the recent years when used as a rescue for
failed initial UCBT. Use of a CBU allows quick second trans-
plants and thus decreases the overall duration of cytopenias.
Second UCBT should be offered as a viable option for children
with a failed ﬁrst UCBT.17
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Objective:We studied the outcome of heavily pre transfused
aplastic anemia patients receiving peripheral blood stem cell
transplant (PBSCT) from matched sibling donor.
Material: 72 consecutive blood/marrow stem cell trans-
plants in 69 aplastic anemia patients over a period of 10 years
in non HEPA ﬁltered single rooms were recorded. Fludar-
abine 30 mg/m
ˇ
2 D-10 to D-5, cyclophosphamide 60 mg/kg/
day D-6 to D-5 and antithymocyte globulin 30 mg/kg/day D-
4 to D-1 were used as conditioning regimen. Cyclosporine
and methotrexate were used for graft versus host disease
(GvHD) prophylaxis. ABO mismatched marrows underwent
RBC depletion. No attempt to reduce antibody titres was
done for ABO mismatched PBSCT.
Results: 63 patients underwent PBSCT; 2 underwent the
procedure twice, 1 of whom had relapsed as acute myeloid
leukemia. Of the 6 patients who received bone marrow stem
cells, 2 relapsed and 1 underwent a successful PBSCT from
the same donor. The median age of patients was 30 years
(range 4-40 years); median time to transplant was 13.5
months (range 1-65 months); median transfusions before
transplant were 22.5 (range 3-10). 28 (38.8%) patients had
pre-existing infections at time of transplant. 65 patients
received empirical antibiotics and 27 received empirical
antifungals for febrile neutropenia during transplant. Posi-
tive blood culture for bacteria was recorded in 10 patients
and a biopsy proven fungus (2 aspergillus, 2 mucor) in 4Figure 1a. Overall survival (OS) in months of 9 patients with SCA after Reduced Toxic
4-45 mo).patients; 5 other patients had possible fungal infection based
on radiological features.
All patients and donors were CMV IgG positive at base-
line. CMV reactivation was noted in 11 patients, 5 of whom
were on steroids for GVHD; 3 patients subsequently suffered
a graft failure.
55/72 (76%) patients are alive at median follow-up of 60
months ranging from 0-118 months. Acute GVHD was seen in
18/72 transplants (25%). 5 patients developed grade III-IV gut
acute GvHD; 4 died. Chronic GvHD was seen in 32% of cases
(20/62; 10 patients died before day 100). However these were
mostly associated with dry skin and changes in pigmentation
which generally subsided over time and well tolerated;1 pa-
tient had nephrotic syndrome at 3 years. Severe cGVHD as per
NIH criteria was seen in only 5 patients. 17 patients had ABO
major mismatch of which 5 patients developed PRCA. PRCA
was managed with steroids and erythropoietin; the longest
duration before recovery was 12 months. 17 patients died.
Cause of early death (<day 100) were: acute GVHD 4, intra-
cranial bleed 4, aspergillus 1, CMV 1, graft rejection 5 (more
than 1 possible cause in some). Cause of death > day 100:
chronic GVHD 1, graft rejection 2, tuberculosis 1.
Conclusions: PBSCT is safe in aplastic anemia patients whose
transplant has been delayed and thereby heavily pre-
transfused. The outcome and survival appear comparable to
those achieved with historical bone marrow transplant data
without apparent increase in morbidity on account of
chronic GvHD.18
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